132 related articles for article (PubMed ID: 23192295)
1. Diagnostic value and therapeutic impact of (18)F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study.
Riemann B; Uhrhan K; Dietlein M; Schmidt D; Kuwert T; Dorn R; Sciuk J; Kodalle T; Schober O
Nuklearmedizin; 2013; 52(1):1-6. PubMed ID: 23192295
[TBL] [Abstract][Full Text] [Related]
2. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
3. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
4. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
5. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
6. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin.
Kim SJ; Lee TH; Kim IJ; Kim YK
Eur J Radiol; 2009 Apr; 70(1):17-24. PubMed ID: 18207685
[TBL] [Abstract][Full Text] [Related]
7. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?
Piccardo A; Foppiani L; Morbelli S; Bianchi P; Barbera F; Biscaldi E; Altrinetti V; Villavecchia G; Cabria M
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):57-65. PubMed ID: 21285923
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of primary papillary thyroid carcinoma with false-negative findings on initial (18)F-FDG PET/CT.
Choi JW; Yoon YH; Yoon YH; Kim SM; Koo BS
Ann Surg Oncol; 2011 May; 18(5):1306-11. PubMed ID: 21140231
[TBL] [Abstract][Full Text] [Related]
9. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
[TBL] [Abstract][Full Text] [Related]
10. Thyroid incidentalomas on FDG PET/CT in patients with non-thyroid cancer - a large retrospective monocentric study.
Kim H; Kim SJ; Kim IJ; Kim K
Onkologie; 2013; 36(5):260-4. PubMed ID: 23689220
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
12. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study.
Grünwald F; Kälicke T; Feine U; Lietzenmayer R; Scheidhauer K; Dietlein M; Schober O; Lerch H; Brandt-Mainz K; Burchert W; Hiltermann G; Cremerius U; Biersack HJ
Eur J Nucl Med; 1999 Dec; 26(12):1547-52. PubMed ID: 10638405
[TBL] [Abstract][Full Text] [Related]
13. (18)F-FDG PET/CT-positive internal mammary lymph nodes: pathologic correlation by ultrasound-guided fine-needle aspiration and assessment of associated risk factors.
Wang CL; Eissa MJ; Rogers JV; Aravkin AY; Porter BA; Beatty JD
AJR Am J Roentgenol; 2013 May; 200(5):1138-44. PubMed ID: 23617501
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
Han A; Xue J; Hu M; Zheng J; Wang X
Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
Shammas A; Degirmenci B; Mountz JM; McCook BM; Branstetter B; Bencherif B; Joyce JM; Carty SE; Kuffner HA; Avril N
J Nucl Med; 2007 Feb; 48(2):221-6. PubMed ID: 17268018
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer.
Grünwald F; Menzel C; Bender H; Palmedo H; Willkomm P; Ruhlmann J; Franckson T; Biersack HJ
Thyroid; 1997 Jun; 7(3):327-35. PubMed ID: 9226199
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ¹³¹I whole-body imaging, ¹³¹I SPECT/CT, and ¹⁸F-FDG PET/CT in the detection of metastatic thyroid cancer.
Oh JR; Byun BH; Hong SP; Chong A; Kim J; Yoo SW; Kang SR; Kim DY; Song HC; Bom HS; Min JJ
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1459-68. PubMed ID: 21505897
[TBL] [Abstract][Full Text] [Related]
18. Postsurgical diagnostic evaluation of patients with differentiated thyroid carcinoma: comparison of ultrasound, iodine-131 scintigraphy and PET with fluorine-18 fluorodeoxyglucose.
Caleo O; Maurea S; Klain M; Salvatore B; Storto G; Mancini M; Pace L; Salvatore M
Radiol Med; 2008 Mar; 113(2):278-88. PubMed ID: 18386128
[TBL] [Abstract][Full Text] [Related]
19. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma.
Zuijdwijk MD; Vogel WV; Corstens FH; Oyen WJ
Nucl Med Commun; 2008 Jul; 29(7):636-41. PubMed ID: 18528186
[TBL] [Abstract][Full Text] [Related]
20. Initial [18F]FDG PET/CT in high-risk DTC patients. A three-year follow-up.
Ruhlmann M; Binse I; Bockisch A; Rosenbaum-Krumme SJ
Nuklearmedizin; 2016 Jun; 55(3):99-103. PubMed ID: 26830084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
